Health Canada licensed psychedelics producer Optimi Health Corp. (OTCQX: OPTHF) has completed the first batch of its proprietary pre-clinical MDMA drug candidate to be used in drug development, clinical trials and individual patients authorized by Health Canada’s Special Access Program (SAP), as well as Australia’s Authorized Prescriber (AP) scheme as of July 1. “Optimi felt it was crucial to fill the void that exists in accessibility to high-quality MDMA drug candidates,” said CEO Bill Ciprick referring to patients and providers anticipating access to psychedelic-assisted therapy. “An inherent level of trust in the safety and purity of …
Source: News